A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer

NCT ID: NCT01358877

Last Updated: 2025-11-28

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

4804 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-11-08

Study Completion Date

2024-11-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This randomized, double-blind, placebo-controlled, two-arm study will assess the safety and efficacy of pertuzumab in addition to chemotherapy plus trastuzumab as adjuvant therapy in participants with operable HER2-positive primary breast cancer. This study will be carried out in collaboration with the Breast International Group (BIG).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pertuzumab + Trastuzumab + Chemotherapy

Participants will receive pertuzumab (840 mg loading dose, then 420 mg) and trastuzumab (8 mg/kg loading dose, then 6 mg/kg) intravenously (IV) every 3 weeks (Q3W) for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 mg/m\^2 + epirubicin 90-120 mg/m\^2 or doxorubicin 50 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m\^2 for 3 cycles, 75 mg/m\^2 in first cycle and 100 mg/m\^2 in subsequent cycles, or 75 mg/m\^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m\^2 once weekly (QW); 2) 4 cycles (Q3W) of doxorubicin 60 mg/m\^2 or epirubicin 90-120 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m\^2 + carboplatin area under the curve (AUC) 6 (up to 900 mg).

Group Type EXPERIMENTAL

5-Fluorouracil

Intervention Type DRUG

5-Fluorouracil will be administered as per the schedule specified in the respective arm.

Carboplatin

Intervention Type DRUG

Carboplatin will be administered as per the schedule specified in the respective arm.

Cyclophosphamide

Intervention Type DRUG

Cyclophosphamide will be administered as per the schedule specified in the respective arm.

Docetaxel

Intervention Type DRUG

Docetaxel will be administered as per the schedule specified in the respective arm.

Doxorubicin

Intervention Type DRUG

Doxorubicin will be administered as per the schedule specified in the respective arm.

Epirubicin

Intervention Type DRUG

Epirubicin will be administered as per the schedule specified in the respective arm.

Paclitaxel

Intervention Type DRUG

Paclitaxel will be administered as per the schedule specified in the respective arm.

Pertuzumab

Intervention Type DRUG

Pertuzumab will be administered as per the schedule specified in the respective arm.

Trastuzumab

Intervention Type DRUG

Trastuzumab will be administered as per the schedule specified in the respective arm.

Placebo + Trastuzumab + Chemotherapy

Participants will receive placebo matching to pertuzumab IV Q3W and trastuzumab (8 milligrams per kilogram \[mg/kg\] loading dose, then 6 mg/kg) IV Q3W for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 milligrams per square meter (mg/m\^2) + epirubicin 90-120 mg/m\^2 or doxorubicin 50 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m\^2 for 3 cycles, 75 mg/m\^2 in first cycle and 100 mg/m\^2 in subsequent cycles, or 75 mg/m\^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m\^2 QW; 2) 4 cycles (Q3W) of doxorubicin 60 mg/m\^2 or epirubicin 90-120 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m\^2 + carboplatin AUC 6 (up to 900 milligrams \[mg\]).

Group Type PLACEBO_COMPARATOR

5-Fluorouracil

Intervention Type DRUG

5-Fluorouracil will be administered as per the schedule specified in the respective arm.

Carboplatin

Intervention Type DRUG

Carboplatin will be administered as per the schedule specified in the respective arm.

Cyclophosphamide

Intervention Type DRUG

Cyclophosphamide will be administered as per the schedule specified in the respective arm.

Docetaxel

Intervention Type DRUG

Docetaxel will be administered as per the schedule specified in the respective arm.

Doxorubicin

Intervention Type DRUG

Doxorubicin will be administered as per the schedule specified in the respective arm.

Epirubicin

Intervention Type DRUG

Epirubicin will be administered as per the schedule specified in the respective arm.

Paclitaxel

Intervention Type DRUG

Paclitaxel will be administered as per the schedule specified in the respective arm.

Placebo

Intervention Type DRUG

Placebo will be administered as per the schedule specified in the respective arm.

Trastuzumab

Intervention Type DRUG

Trastuzumab will be administered as per the schedule specified in the respective arm.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

5-Fluorouracil

5-Fluorouracil will be administered as per the schedule specified in the respective arm.

Intervention Type DRUG

Carboplatin

Carboplatin will be administered as per the schedule specified in the respective arm.

Intervention Type DRUG

Cyclophosphamide

Cyclophosphamide will be administered as per the schedule specified in the respective arm.

Intervention Type DRUG

Docetaxel

Docetaxel will be administered as per the schedule specified in the respective arm.

Intervention Type DRUG

Doxorubicin

Doxorubicin will be administered as per the schedule specified in the respective arm.

Intervention Type DRUG

Epirubicin

Epirubicin will be administered as per the schedule specified in the respective arm.

Intervention Type DRUG

Paclitaxel

Paclitaxel will be administered as per the schedule specified in the respective arm.

Intervention Type DRUG

Pertuzumab

Pertuzumab will be administered as per the schedule specified in the respective arm.

Intervention Type DRUG

Placebo

Placebo will be administered as per the schedule specified in the respective arm.

Intervention Type DRUG

Trastuzumab

Trastuzumab will be administered as per the schedule specified in the respective arm.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Perjeta® Herceptin®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Non-metastatic operable primary invasive HER2-positive carcinoma of the breast that is histologically confirmed, and adequately excised
* Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to (\</=) 1
* Known hormone receptor status (estrogen receptor and progesterone receptor)
* The interval between definitive surgery for breast cancer and the first dose of chemotherapy must be no more than 8 weeks (56 days). The first cycle of chemotherapy must be administered within 7 days of randomization or on Day 56, whichever occurs first
* Baseline left ventricular ejection fraction (LVEF) greater than or equal to (\>/=) 55 percent (%) measured by echocardiogram (ECHO) or Multiple-Gated Acquisition (MUGA) Scan
* Confirmed HER2 positive status
* Completion of all necessary baseline laboratory and radiologic investigations prior to randomization
* Women of childbearing potential and male participants with partners of childbearing potential must agree to use effective contraception (as defined by the protocol) by the participant and/or partner for the duration of the study treatment and for at least 7 months after the last dose of study drug

Exclusion Criteria

* History of any prior (ipsi- and/or contralateral) invasive breast cancer
* History of non-breast malignancies within the 5 years prior to study entry, except for carcinoma in situ of the cervix, carcinoma in situ of the colon, melanoma in situ, and basal cell and squamous cell carcinomas of the skin
* Any "clinical" T4 tumor as defined by primary tumor/regional lymph nodes/distant metastasis (TNM), including inflammatory breast cancer
* Any node-negative tumor
* Any previous systemic chemotherapy for cancer or radiotherapy for cancer
* Prior use of anti-HER2 therapy for any reason or other prior biologic or immunotherapy for cancer
* Concurrent anti-cancer treatment in another investigational trial
* Serious cardiac or cardiovascular disease or condition
* Other concurrent serious diseases that may interfere with planned treatment including severe pulmonary conditions/illness
* Abnormal laboratory tests immediately prior to randomization
* Pregnant or lactating women
* Sensitivity to any of the study medications or any of the ingredients or excipients of these medications
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Genentech, Inc.

INDUSTRY

Sponsor Role collaborator

Breast International Group

OTHER

Sponsor Role collaborator

Hoffmann-La Roche

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Clinical Trials

Role: STUDY_DIRECTOR

Hoffmann-La Roche

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

HonorHealth Research Institute ? Bisgrove

Scottsdale, Arizona, United States

Site Status

Providence Regional Medical Center

Everett, California, United States

Site Status

Marin Cancer Care Inc

Greenbrae, California, United States

Site Status

Kaiser Permanente - Hayward

Hayward, California, United States

Site Status

UCSD Moores Cancer Center

La Jolla, California, United States

Site Status

Cedars-Sinai Medical Center

Los Angeles, California, United States

Site Status

Kaiser Permanente - Oakland

Oakland, California, United States

Site Status

Kaiser Permanente - Roseville

Roseville, California, United States

Site Status

Sutter Cancer Center

Sacramento, California, United States

Site Status

Kaiser Permanente Sacramento Medical Center

Sacramento, California, United States

Site Status

Southern California Kaiser Permanente

San Diego, California, United States

Site Status

K. Permanente - San Fransisco

San Francisco, California, United States

Site Status

K. Permanente - San Jose

San Jose, California, United States

Site Status

K. Permanente - Santa Clara

Santa Clara, California, United States

Site Status

K. Permanente - S. San Fran

South San Francisco, California, United States

Site Status

Kaiser Permanente

Vallejo, California, United States

Site Status

K. Permanente - Walnut Creek

Walnut Creek, California, United States

Site Status

Rocky Mountain Cancer Center - Denver

Denver, Colorado, United States

Site Status

Lutheran Hematology &Oncology

Wheat Ridge, Colorado, United States

Site Status

Eastern Ct Hema/Onco Assoc

Norwich, Connecticut, United States

Site Status

Washington Cancer Institute at MedStar Washington Hospital Center.

Washington D.C., District of Columbia, United States

Site Status

Georgetown U

Washington D.C., District of Columbia, United States

Site Status

Florida Cancer Specialists

Fort Myers, Florida, United States

Site Status

Memorial Cancer Institute

Hollywood, Florida, United States

Site Status

Mayo Clinic-Jacksonville

Jacksonville, Florida, United States

Site Status

Cancer Specialists

Jacksonville, Florida, United States

Site Status

Ocala Oncology Center

Ocala, Florida, United States

Site Status

Memorial Breast Cancer Center

Pembroke Pines, Florida, United States

Site Status

Hematology Oncology Associates of the Treasure Coast

Port Saint Lucie, Florida, United States

Site Status

Florida Cancer Specialists

St. Petersburg, Florida, United States

Site Status

Florida Cancer Specialists, Research Department

West Palm Beach, Florida, United States

Site Status

Phoebe Putney Memorial Hospital

Albany, Georgia, United States

Site Status

Georgia Cancer Specialists

Atlanta, Georgia, United States

Site Status

Northwest Georgia Oncology Centers PC - Marietta

Marietta, Georgia, United States

Site Status

Kootenai Cancer Center

Post Falls, Idaho, United States

Site Status

Rush University Medical Center

Chicago, Illinois, United States

Site Status

Uni of Chicago

Chicago, Illinois, United States

Site Status

Ingalls Memorial Hospital

Harvey, Illinois, United States

Site Status

Loyola University Med Center

Maywood, Illinois, United States

Site Status

Edward Cancer Center Naperville

Naperville, Illinois, United States

Site Status

Illinois Cancer Care

Peoria, Illinois, United States

Site Status

Edward Cancer Center Plainfield

Plainfield, Illinois, United States

Site Status

Quincy Medical Group

Quincy, Illinois, United States

Site Status

Carle Foundation

Urbana, Illinois, United States

Site Status

University of Iowa

Iowa City, Iowa, United States

Site Status

Cancer Center of Kansas

Wichita, Kansas, United States

Site Status

Cancer Center of Acadiana at Lafayette General

Lafayette, Louisiana, United States

Site Status

Cancer Care of Maine

Bangor, Maine, United States

Site Status

New England Cancer Specialists

Scarborough, Maine, United States

Site Status

Mercy Medical Center

Baltimore, Maryland, United States

Site Status

Weinberg CA Inst Franklin Sq

Baltimore, Maryland, United States

Site Status

Maryland Oncology & Hematology, PA

Bethesda, Maryland, United States

Site Status

Massachusetts General Hospital.

Boston, Massachusetts, United States

Site Status

Boston Medical Center

Boston, Massachusetts, United States

Site Status

Beth Israel Deac Med Ctr

Boston, Massachusetts, United States

Site Status

Dana Farber Can Ins

Boston, Massachusetts, United States

Site Status

Berkshire Hematology, Oncology Pc

Pittsfield, Massachusetts, United States

Site Status

Grand Rapids Clinical Oncology Program

Grand Rapids, Michigan, United States

Site Status

West Michigan Cancer Center

Kalamazoo, Michigan, United States

Site Status

Southdale Cancer Clinic

Edina, Minnesota, United States

Site Status

Coborn Cancer Center

Saint Cloud, Minnesota, United States

Site Status

Metro-Minnesota Community Oncology Research Consortium

Saint Louis Park, Minnesota, United States

Site Status

Jackson Oncology Associates, PLLC

Jackson, Mississippi, United States

Site Status

Washington University School of Medicine

St Louis, Missouri, United States

Site Status

Heartland CCOP/Missouri Baptist Medical Center

St Louis, Missouri, United States

Site Status

Cancer Alliance of Nebraska

Lincoln, Nebraska, United States

Site Status

Cancer Alliance of Nebraska

Omaha, Nebraska, United States

Site Status

Dartmouth Hitchcock Med Center

Lebanon, New Hampshire, United States

Site Status

Saint Barnabas Medical Center

Livingston, New Jersey, United States

Site Status

New York Oncology Hematology, P.C.

Albany, New York, United States

Site Status

Roswell Park Cancer Inst.

Buffalo, New York, United States

Site Status

Mount Sinai Beth Israel Medical Center

New York, New York, United States

Site Status

Mount Sinai Beth Israel Comprehensive Cancer Center

New York, New York, United States

Site Status

Mount Sinai West

New York, New York, United States

Site Status

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Site Status

SUNY Upstate Medical University

Syracuse, New York, United States

Site Status

Montefiore Medical Center

The Bronx, New York, United States

Site Status

University of North Carolina-Chapel Hill

Chapel Hill, North Carolina, United States

Site Status

Carolina Oncology Specialists, PA - Hickory

Hickory, North Carolina, United States

Site Status

Oncology Hematology Care Inc

Cincinnati, Ohio, United States

Site Status

The Mark H. Zangmeister Ctr

Columbus, Ohio, United States

Site Status

Dayton Clinical Oncology Prog

Dayton, Ohio, United States

Site Status

Toledo Clinic Cancer Center

Toledo, Ohio, United States

Site Status

Northwest Cancer Specialists - Portland (NE Hoyt St)

Portland, Oregon, United States

Site Status

Abramson Cancer Center

Philadelphia, Pennsylvania, United States

Site Status

Albert Einstein Healthcare Network

Philadelphia, Pennsylvania, United States

Site Status

Magee Womens Hospital

Pittsburgh, Pennsylvania, United States

Site Status

Charleston Oncology, P .A

Charleston, South Carolina, United States

Site Status

Roper Bon Secours St. Francis Cancer Center

Charleston, South Carolina, United States

Site Status

South Carolina Oncology Associates - SCRI

Columbia, South Carolina, United States

Site Status

University of Missouri-Columbia

Columbia, South Carolina, United States

Site Status

Cancer Centers of the Carolina

Greenville, South Carolina, United States

Site Status

Sanford USD School of Medicine

Sioux Falls, South Dakota, United States

Site Status

Tennessee Oncology , PLLC - Chattanooga

Chattanooga, Tennessee, United States

Site Status

Tennessee Oncology - Nashville

Nashville, Tennessee, United States

Site Status

Vanderbilt Breast Center at One Hundred Oaks

Nashville, Tennessee, United States

Site Status

Texas Oncology-Medical City Dallas

Dallas, Texas, United States

Site Status

Texas Oncology - DFW at Dallas Presbyterian Hospital

Dallas, Texas, United States

Site Status

Texas Oncology - DFW

Dallas, Texas, United States

Site Status

Texas Oncology-El Paso Cancer Treatment Center Grandview

El Paso, Texas, United States

Site Status

Texas Oncology - DFW Fort Worth

Fort Worth, Texas, United States

Site Status

The Center for Cancer and Blood Disorders - Fort Worth

Fort Worth, Texas, United States

Site Status

Texas Oncology, P.A. - Garland

Garland, Texas, United States

Site Status

Texas Oncology - Houston (Gessner)

Houston, Texas, United States

Site Status

Cancer Care Centers of South Texas-HOAST - San Antonio

New Braunfels, Texas, United States

Site Status

Texas Oncology - DFW Plano

Plano, Texas, United States

Site Status

Texas Oncology-Tyler

Tyler, Texas, United States

Site Status

Community Cancer Trials of Utah

Ogden, Utah, United States

Site Status

Wellmonth Physician Services

Bristol, Virginia, United States

Site Status

Virginia Cancer Institute

Richmond, Virginia, United States

Site Status

Providence St. Mary Regional Cancer Center

Walla Walla, Washington, United States

Site Status

West Virginia University Hospitals Inc

Morgantown, West Virginia, United States

Site Status

Green Bay Oncology/St. Mary?s Hospital

Green Bay, Wisconsin, United States

Site Status

Marshfield Clinic

Marshfield, Wisconsin, United States

Site Status

Centro Medico San Roque

San Miguel de Tucumán, , Argentina

Site Status

Lismore Base Hospital

Lismore, New South Wales, Australia

Site Status

Mater Misericordiae Hospital

Sydney, New South Wales, Australia

Site Status

Newcastle Mater Misericordiae Hospital

Waratah, New South Wales, Australia

Site Status

Westmead Hospital

Westmead, New South Wales, Australia

Site Status

Wesley Medical Centre

Auchenflower, Queensland, Australia

Site Status

Mater Hospital

Brisbane, Queensland, Australia

Site Status

Royal Adelaide Hospital

Adelaide, South Australia, Australia

Site Status

Royal Hobart Hospital

Hobart, Tasmania, Australia

Site Status

Monash Medical Centre

EAST Bentleigh, Victoria, Australia

Site Status

Geelong Hospital

Geelong, Victoria, Australia

Site Status

Austin Hospital

Heidelberg, Victoria, Australia

Site Status

Peter Maccallum Cancer Institute

Melbourne, Victoria, Australia

Site Status

Sir Charles Gairdner Hospital

Perth, Western Australia, Australia

Site Status

Lkh-Univ. Klinikum Graz

Graz, , Austria

Site Status

Tiroler Landeskrankenanstalten Ges.M.B.H.

Innsbruck, , Austria

Site Status

Ordensklinikum Linz Barmherzige Schwestern

Linz, , Austria

Site Status

Lhk Feldkirch

Rankweil, , Austria

Site Status

Lkh Salzburg - Univ. Klinikum Salzburg

Salzburg, , Austria

Site Status

A. Ö. Krankenhaus Der Barmherzigen Brüder

Sankt Veit an der Glan, , Austria

Site Status

Medizinische Universität Wien; Klinik für Frauenheilkunde

Vienna, , Austria

Site Status

Medizinische Universität Wien; Klinik für Innere Medizin; Abteilung für Onkologie

Vienna, , Austria

Site Status

Krankenhaus Der Stadt Wien-Hietzing

Vienna, , Austria

Site Status

Lkh Vöcklabruck

Vöcklabruck, , Austria

Site Status

Klinikum Kreuzschwestern Wels

Wels, , Austria

Site Status

Institut Jules Bordet

Anderlecht, , Belgium

Site Status

GHdC Site Les Viviers

Charleroi, , Belgium

Site Status

UZ Antwerpen

Edegem, , Belgium

Site Status

Jessa Zkh (Campus Virga Jesse)

Hasselt, , Belgium

Site Status

AZ Groeninge

Kortrijk, , Belgium

Site Status

UZ Leuven Gasthuisberg

Leuven, , Belgium

Site Status

CHU de Liège (Sart Tilman)

Liège, , Belgium

Site Status

Clinique Ste-Elisabeth

Namur, , Belgium

Site Status

ZAS Sint Augustinus Wilrijk

Wilrijk, , Belgium

Site Status

UMHAT Tsaritsa Yoanna - ISUL

Sofia, , Bulgaria

Site Status

SHATO - Sofia

Sofia, , Bulgaria

Site Status

SHATOD Dr. Marko Antonov Markov-Varna, EOOD

Varna, , Bulgaria

Site Status

Arthur J.E. Child Comprehensive Cancer Center

Calgary, Alberta, Canada

Site Status

Cross Can Inst

Edmonton, Alberta, Canada

Site Status

BC Cancer Agency, CSI

Kelowna, British Columbia, Canada

Site Status

BC Cancer ? Surrey

Surrey, British Columbia, Canada

Site Status

BCCA-Vancouver Cancer Centre

Vancouver, British Columbia, Canada

Site Status

Bcca - Vancouver Island Cancer Centre

Victoria, British Columbia, Canada

Site Status

CancerCare Manitoba

Winnipeg, Manitoba, Canada

Site Status

Queen Elizabeth II Health Sciences Centre

Halifax, Nova Scotia, Canada

Site Status

Northeastern Ontario

Greater Sudbury, Ontario, Canada

Site Status

Hamilton Health Sciences - Juravinski Cancer Centre

Hamilton, Ontario, Canada

Site Status

Cancer Centre of Southeastern Ontario

Kingston, Ontario, Canada

Site Status

London Health Sciences Centre

London, Ontario, Canada

Site Status

Credit Valley Hospital/Carlo Fidani Peel Regional Cancer Centre

Mississauga, Ontario, Canada

Site Status

Southlake Regional Health Center

Newmarket, Ontario, Canada

Site Status

Ottawa Regional Cancer Centre

Ottawa, Ontario, Canada

Site Status

Niagara Health Systems - St. Catherines General Site

St. Catharines, Ontario, Canada

Site Status

Sunnybrook Odette Cancer Centre

Toronto, Ontario, Canada

Site Status

Mount Sinai Hospital

Toronto, Ontario, Canada

Site Status

Princess Margaret Cancer Center

Toronto, Ontario, Canada

Site Status

Hopital Maisonneuve- Rosemont

Montreal, Quebec, Canada

Site Status

Hopital Sacre-Coeur Research Centre

Montreal, Quebec, Canada

Site Status

Allan Blair Cancer Centre

Regina, Saskatchewan, Canada

Site Status

Hopital du Saint Sacrement

Québec, , Canada

Site Status

INTOP

Providencia, , Chile

Site Status

Fundacion Arturo Lopez Perez

Santiago, , Chile

Site Status

Cancer Hospital Chinese Academy of Medical Sciences.

Beijing, , China

Site Status

The Affiliated Hospital of Military Medical Sciences(The 307th Hospital of Chinese PLA)

Beijing, , China

Site Status

Jilin Cancer Hospital

Changchun, , China

Site Status

the First Hospital of Jilin University

Changchun, , China

Site Status

Hu Nan Provincial Cancer Hospital

Changsha, , China

Site Status

Sichuan Provincial People's Hospital

Chengdu, , China

Site Status

Fujian Medical University Union Hospital

Fujian, , China

Site Status

The 900th Hospital of PLA joint service support force

Fuzhou, , China

Site Status

Sun Yet-sen University Cancer Center

Guangzhou, , China

Site Status

Guangdong General Hospital

Guangzhou, , China

Site Status

The First Affiliated Hospital of College of Medicine, Zhejiang University

Hangzhou, , China

Site Status

Harbin Medical University Cancer Hospital; Dept. of Breast Surgery

Harbin, , China

Site Status

Harbin Medical University Cancer Hospital

Harbin, , China

Site Status

The 1st Affiliated Hospital of Nanchang Unversity

Nanchang, , China

Site Status

Shanghai Jiao Tong University School of Medicine (SJTUSM) - Ruijin Hospital (GuangCi Hospital)

Shanghai, , China

Site Status

Fudan University Shanghai Cancer Center

Shanghai, , China

Site Status

Shanghai First People's Hospital

Shanghai, , China

Site Status

Changhai Hospital of Shanghai

Shanghai, , China

Site Status

Hebei Medical University Fourth Hospital

Shijiazhuang, , China

Site Status

Xiehe Hospital, Tongji Medical College Huazhong University of Science & Technology

Wuhan, , China

Site Status

Tongji Hosp, Tongji Med. Col, Huazhong Univ. of Sci. & Tech

Wuhan, , China

Site Status

Hubei Cancer Hospital

Wuhan, , China

Site Status

Fundacion Cardioinfantil

Bogotá, , Colombia

Site Status

Inst. Nacional de Cancerologia

Bogotá, , Colombia

Site Status

Hospital Pablo Tobon Uribe

Medellin-Antioquia, , Colombia

Site Status

Oncomedica S.A.

Montería, , Colombia

Site Status

Uni Hospital Split

Split, , Croatia

Site Status

General Hospital Varazdin

Varaždin, , Croatia

Site Status

Clinical Hospital Centre Zagreb

Zagreb, , Croatia

Site Status

Masarykuv onkologicky ustav

Brno, , Czechia

Site Status

Fakultni Nemocnice Hradec Kralove

Hradec Králové, , Czechia

Site Status

Fakultni nemocnice Olomouc

Olomouc, , Czechia

Site Status

MULTISCAN, s.r.o., Radiologicke centrum Pardubice

Pardubice, , Czechia

Site Status

Aalborg Universitetshospital

Aalborg, , Denmark

Site Status

Rigshospitalet

Copenhagen, , Denmark

Site Status

Sydvestjysk Sygehus Esbjerg

Esbjerg, , Denmark

Site Status

Herlev Hospital

Herlev, , Denmark

Site Status

Nordsjællands Hospital, Hillerød, Onkologisk Afdeling

Hillerød, , Denmark

Site Status

Sjællands Universitetshospital, Næstved

Næstved, , Denmark

Site Status

Odense Universitetshospital, Onkologisk Afdeling R

Odense C, , Denmark

Site Status

Sygehus Syd Roskilde

Roskilde, , Denmark

Site Status

Vejle Sygehus

Vejle, , Denmark

Site Status

Hospital Oncologia

El Salvador, , El Salvador

Site Status

Clinique De L Europe

Amiens, , France

Site Status

ICO Paul Papin

Angers, , France

Site Status

HOP Prive Arras Les Bonnettes

Arras, , France

Site Status

Institut Sainte Catherine

Avignon, , France

Site Status

ICONE

Bezannes, , France

Site Status

Institut Bergonie

Bordeaux, , France

Site Status

Polyclinique Bordeaux Nord

Bordeaux, , France

Site Status

Hopital Augustin Morvan

Brest, , France

Site Status

Centre Francois Baclesse

Caen, , France

Site Status

Centre Jean Perrin

Clermont-Ferrand, , France

Site Status

Centre Leonard De Vinci

Dechy, , France

Site Status

Centre Georges-François Lecler

Dijon, , France

Site Status

Institut Daniel Hollard

Grenoble, , France

Site Status

Centre Hospitalier Departemental Les Oudairies

La Roche-sur-Yon, , France

Site Status

Clinique des Ormeaux

Le Havre, , France

Site Status

Centre Oscar Lambret

Lille, , France

Site Status

Hopital Dupuytren

Limoges, , France

Site Status

Centre Leon Berard

Lyon, , France

Site Status

Institut Paoli Calmettes

Marseille, , France

Site Status

Institut régional du Cancer Montpellier

Montpellier, , France

Site Status

Polyclinique De Gentilly

Nancy, , France

Site Status

Centre Antoine Lacassagne

Nice, , France

Site Status

Institut de cancerologie du Gard

Nîmes, , France

Site Status

Institut Curie

Paris, , France

Site Status

Ch Pitie Salpetriere

Paris, , France

Site Status

Polyclinique Francheville

Périgueux, , France

Site Status

Clinique Armoricaine Radiologie

Plérin, , France

Site Status

Chu De Poitiers

Poitiers, , France

Site Status

Institut Jean Godinot

Reims, , France

Site Status

Centre Eugene Marquis

Rennes, , France

Site Status

Centre Henri Becquerel

Rouen, , France

Site Status

ICL

Saint Prient En Jarez, , France

Site Status

Centre Rene Huguenin

Saint-Cloud, , France

Site Status

Ico Rene Gauducheau

Saint-Herblain, , France

Site Status

Institut d'oncologie de l'Orangerie

Strasbourg, , France

Site Status

Hopital Hautepierre

Strasbourg, , France

Site Status

Institut Claudius Regaud

Toulouse, , France

Site Status

Clinique Pasteur

Toulouse, , France

Site Status

Centre Alexis Vautrin

Vandœuvre-lès-Nancy, , France

Site Status

Institut Gustave Roussy

Villejuif, , France

Site Status

Gesundheitszentrum St. Marien GmbH

Amberg, , Germany

Site Status

Hochwaldkrankenhaus

Bad Nauheim, , Germany

Site Status

Praxis Dr. Schoenegg

Berlin, , Germany

Site Status

HELIOS Klinikum Berlin-Buch

Berlin, , Germany

Site Status

Frauenarzt-Zentrum Zehlendorf an der Teltower Eiche

Berlin, , Germany

Site Status

Onkologische Schwerpunktpraxis Bielefeld

Bielefeld, , Germany

Site Status

Universitätsklinikum Bonn

Bonn, , Germany

Site Status

Klinikum Sindelfingen-Böblingen

Böblingen, , Germany

Site Status

Praxis Dr. Ralf Lorenz

Braunschweig, , Germany

Site Status

Hämato-Onkologie im Medicum/Home

Bremen, , Germany

Site Status

Klinikum Chemnitz gGmbH

Chemnitz, , Germany

Site Status

Uniklinik Köln, Klinik und Poliklinik und Geburtshilfe

Cologne, , Germany

Site Status

St. Elisabeth Krankenhaus Köln GmbH

Cologne, , Germany

Site Status

DONAU ISAR Klinikum Deggendorf

Deggendorf, , Germany

Site Status

St. Johannes-Hospital

Dortmund, , Germany

Site Status

Universitätsklinikum "Carl Gustav Carus"

Dresden, , Germany

Site Status

Universitätsklinikum Düsseldorf

Düsseldorf, , Germany

Site Status

Luisenkrankenhaus GmbH & Co. KG., Brustzentrum

Düsseldorf, , Germany

Site Status

Praxis für Hamatologie und Onkologie

Erfurt, , Germany

Site Status

Universitätsklinikum Erlangen

Erlangen, , Germany

Site Status

Klinikum Esslingen

Esslingen am Neckar, , Germany

Site Status

Klinik Johann Wolfgang von Goethe Uni

Frankfurt, , Germany

Site Status

Städtische Kliniken Frankfurt am Main Höchst

Frankfurt, , Germany

Site Status

Hämatologisch-Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus

Frankfurt am Main, , Germany

Site Status

Praxis für Interdisziplinäre Onkologie und Hämatologie GbR

Freiburg im Breisgau, , Germany

Site Status

Dres.Jochen Wilke und Harald Wagner

Fürth, , Germany

Site Status

Universitätsklinikum Greifswald

Greifswald, , Germany

Site Status

Universitätsklinikum Halle (Saale)

Halle, , Germany

Site Status

Universitätsklinikum Hamburg-Eppendorf

Hamburg, , Germany

Site Status

SANA Klinikum Hameln-Pyrmont

Hamelin, , Germany

Site Status

Diakovere Henriettenstift, Frauenklinik

Hanover, , Germany

Site Status

MVZ Onko Medical GmbH Hannover, Ralf Lohse (Geschäftsführer)

Hanover, , Germany

Site Status

Nationales Centrum für Tumorerkrankungen (NCT)

Heidelberg, , Germany

Site Status

Praxisgemeinschaft

Hildesheim, , Germany

Site Status

Universitätsklinikum des Saarlandes

Homburg/Saar, , Germany

Site Status

ViDia Christliche Kliniken Karlsruhe, Vincentius-Diakonissen-Kliniken gAG

Karlsruhe, , Germany

Site Status

Elisabeth-Krankenhaus Brustzentrum

Kassel, , Germany

Site Status

Klinikum Kassel GmbH

Kassel, , Germany

Site Status

UNI-Klinikum Campus Kiel Klinik für Gynäkologie und Geburtshilfe

Kiel, , Germany

Site Status

Klinikum Landshut Frauenklinik

Landshut, , Germany

Site Status

Sankt Elisabeth Krankenhaus

Leipzig, , Germany

Site Status

Praxisklinik Krebsheilkunde für Frauen / Brustzentrum (Dres. Kittel/Klare)

Lichtenberg, , Germany

Site Status

Evangelisches Krankenhaus

Ludwigsfelde, , Germany

Site Status

Universitätsklinikum Schleswig-Holstein / Campus Lübeck

Lübeck, , Germany

Site Status

Universitätsmedizin Mainz

Mainz, , Germany

Site Status

Brustzentrum Rhein-Ruhr Servicegesellschaft mbH

Mönchengladbach, , Germany

Site Status

Klinikum der Universität München

München, , Germany

Site Status

Rotkreuzklinikum München

München, , Germany

Site Status

Klinikum rechts der Isar der TU München

München, , Germany

Site Status

Universitätsklinikum Münster

Münster, , Germany

Site Status

Sana Klinikum Offenbach GmbH

Offenbach, , Germany

Site Status

Medizinisches Versorgungszentrum am Klinikum Oldenburg GmbH

Oldenburg, , Germany

Site Status

Hämatologisch/Onkologische Praxis Prof. Dr. Decker, Studienzentrum

Ravensburg, , Germany

Site Status

Oncologianova GmbH

Recklinghausen, , Germany

Site Status

RoMed Klinikum Rosenheim

Rosenheim, , Germany

Site Status

Universitätsfrauen- und Poliklinik am Klinikum Suedstadt

Rostock, , Germany

Site Status

MVZ für Hämatologie, Onkologie, Strahlentherapie und Palliativmedizin -

Stade, , Germany

Site Status

Klinikum Mutterhaus der Borromaeerinnen gGmbH

Trier, , Germany

Site Status

Universitätsklinik Tübingen

Tübingen, , Germany

Site Status

Universitätsklinikum Ulm Am Michelsberg

Ulm, , Germany

Site Status

Dres. Arnd Nusch Naser Ali-Mohammad Kalhori und Werner Langer

Velbert, , Germany

Site Status

Schwarzwald-Baar Klinikum Klinik für Frauenheilkunde und Geburtshilfe

Villingen-Schwenningen, , Germany

Site Status

St. Josefs-Hospital Wiesbaden

Wiesbaden, , Germany

Site Status

Marien-Hospital Witten

Witten, , Germany

Site Status

Hämatologisch-Onkologische Schwerpunktpraxis Dres. Schlag & Schöttker

Würzburg, , Germany

Site Status

Grupo Angeles

Guatemala City, , Guatemala

Site Status

Queen Mary Hospital; Dept. of Clinical Oncology

Hong Kong, , Hong Kong

Site Status

Queen Mary Hospital; Surgery

Hong Kong, , Hong Kong

Site Status

Orszagos Onkologiai Intezet

Budapest, , Hungary

Site Status

Magyar Honvedseg Egeszsegugyi Kozpont

Budapest, , Hungary

Site Status

Debreceni Egyetem, Klinikai Kozpont, Onkologiai Klinika

Debrecen, , Hungary

Site Status

Petz Aladar Megyei Oktato Korhaz

Győr, , Hungary

Site Status

Békés Megyei Pándy Kálmán Kórház

Gyula, , Hungary

Site Status

Bács-Kiskun Vármegyei Oktatókórház

Kecskemét, , Hungary

Site Status

Szegedi Tudomanyegyetem, AOK, Szent-Gyorgyi Albert Klinikai Kozpont, Onkoterapias Klinika

Szeged, , Hungary

Site Status

Cork Uni Hospital

Cork, , Ireland

Site Status

Mater Misericordiae Uni Hospital

Dublin, , Ireland

Site Status

St. James Hospital

Dublin, , Ireland

Site Status

Beaumont Hospital

Dublin, , Ireland

Site Status

St Vincent'S Uni Hospital

Dublin, , Ireland

Site Status

Galway University Hospital

Galway, , Ireland

Site Status

University Hospital Limerick - Oncology

Limerick, , Ireland

Site Status

Rambam Medical Center

Haifa, , Israel

Site Status

Rabin MC

Petah Tikva, , Israel

Site Status

Chaim Sheba Medical Center

Ramat Gan, , Israel

Site Status

Kaplan Medical Center

Rehovot, , Israel

Site Status

Sourasky / Ichilov Hospital

Tel Aviv, , Israel

Site Status

Ospedale Antonio Perrino

Brindisi, Apulia, Italy

Site Status

Campus Universitario S.Venuta

Catanzaro, Calabria, Italy

Site Status

AORN'S.G.Moscati

Avellino, Campania, Italy

Site Status

IRCCS Istituto Nazionale Tumori Fondazione Pascale

Napoli, Campania, Italy

Site Status

Ist. Uni Federico Ii

Napoli, Campania, Italy

Site Status

Azienda Ospedaliero-Universitaria S.Orsola-Malpighi

Bologna, Emilia-Romagna, Italy

Site Status

Ospedale Ramazzini

Carpi, Emilia-Romagna, Italy

Site Status

Arcispedale Santa Maria Nuova

Reggio Emilia, Emilia-Romagna, Italy

Site Status

Irccs Centro Di Riferimento Oncologico (CRO)

Aviano, Friuli Venezia Giulia, Italy

Site Status

Divisione Onc Med dell'Azienda

Udine, Friuli Venezia Giulia, Italy

Site Status

Ospedale Belcolle Di Viterbo

Viterbo, Lazio, Italy

Site Status

Ente Ospedaliero Ospedali Galliera

Genoa, Liguria, Italy

Site Status

Az. Osp. Uni Ria San Martino

Genoa, Liguria, Italy

Site Status

IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST)

Genoa, Liguria, Italy

Site Status

Asst Degli Spedali Civili Di Brescia

Brescia, Lombardy, Italy

Site Status

Asst Di Lecco

Lecco, Lombardy, Italy

Site Status

Ospedale Mater Salutis

Legnago, Lombardy, Italy

Site Status

Irccs Istituto Europeo Di Oncologia (IEO)

Milan, Lombardy, Italy

Site Status

Policlinico di Monza

Monza, Lombardy, Italy

Site Status

IRCCS Fondazione Maugeri

Pavia, Lombardy, Italy

Site Status

IRCCS Istituto Clinico Humanitas

Rozzano, Lombardy, Italy

Site Status

Az. Osp. Di Busto P.O. Di Saronno

Saronno, Lombardy, Italy

Site Status

Fondazione Del Piemonte Per L'oncologia Ircc Di Candiolo

Candiolo, Piedmont, Italy

Site Status

Ospedale S. Croce Di Fano

Fano, The Marches, Italy

Site Status

Ospedale Di Bolzano

Bolzano, Trentino-Alto Adige, Italy

Site Status

Nuovo Ospedale di Prato S. Stefano - Azienda USL Toscana Centro

Prato, Tuscany, Italy

Site Status

Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia

Perugia, Umbria, Italy

Site Status

Azienda Ospedaliera S. Maria - Terni

Terni, Umbria, Italy

Site Status

Aichi Cancer Center Hospital, Breast Oncology

Aichi, , Japan

Site Status

Chiba Cancer Center

Chiba, , Japan

Site Status

National Cancer Center Hospital East

Chiba, , Japan

Site Status

Natl Hosp Org Shikoku

Ehime, , Japan

Site Status

National Hospital Organization Kyushu Cancer Center

Fukuoka, , Japan

Site Status

Gunma University Hospital

Gunma, , Japan

Site Status

Hiroshima City Hiroshima Citizens Hospital

Hiroshima, , Japan

Site Status

Sagara Hospital

Kagoshima, , Japan

Site Status

St. Marianna University School of Medicine Hospital, Breast and Endocrine Surgery

Kanagawa, , Japan

Site Status

Tokai University Hospital, Breast Surgery

Kanagawa, , Japan

Site Status

Kumamoto Shinto General Hospital

Kumamoto, , Japan

Site Status

Kyoto University Hospital

Kyoto, , Japan

Site Status

Niigata Cancer Ctr Hospital

Niigata, , Japan

Site Status

Iwate Med Univ School of Med

Numakunai, , Japan

Site Status

National Hospital Organization Osaka National Hospital

Osaka, , Japan

Site Status

Osaka International Cancer Institute

Osaka, , Japan

Site Status

Saitama Medical University International Medical Center

Saitama, , Japan

Site Status

Saitama Cancer Center, Breast Oncology

Saitama, , Japan

Site Status

Shizuoka Cancer Center

Shizuoka, , Japan

Site Status

Shizuoka General Hospital

Shizuoka, , Japan

Site Status

Jichi Medical School

Tochigi, , Japan

Site Status

National Cancer Center Hospital

Tokyo, , Japan

Site Status

Tokyo Metropolitan

Tokyo, , Japan

Site Status

The Cancer Inst. Hosp. of JFCR

Tokyo, , Japan

Site Status

Tokyo Medical Uni. Hospital

Tokyo, , Japan

Site Status

Centro Estatal de Oncología de Campeche

Campehe, Campeche, Mexico

Site Status

Fundacion Rodolfo Padilla Padilla A.C.

León, Guanajuato, Mexico

Site Status

Núcleo de Especialidades Oncológicas

Guadalajara, Jalisco, Mexico

Site Status

Hospital General de México

Mexico City, Mexico CITY (federal District), Mexico

Site Status

Hospital Angeles Metropolitano

Mexico City, Mexico CITY (federal District), Mexico

Site Status

Centro Universitario Contra El Cancer

Monterrey, Nuevo León, Mexico

Site Status

Centro de Diagnóstico y Tratamiento Integral de Mama, Hospital San José Tec de Monterrey

Montrrey, Nuevo León, Mexico

Site Status

Oaxaca Site Management Organization

Oaxaca City, Oaxaca, Mexico

Site Status

Médicos Especialistas en Cáncer SC

Aguascalientes, , Mexico

Site Status

Centro Estatal De Cancerologia De Durango

Durango, , Mexico

Site Status

Cancerologia de Queretaro

Querétaro, , Mexico

Site Status

Medisch Centrum Alkmaar

Alkmaar, , Netherlands

Site Status

Amphia ziekenhuis, locatie langendijk

Breda, , Netherlands

Site Status

Reinier de Graaf Gasthuis

Delft, , Netherlands

Site Status

Academish Ziekenhuis Maastricht (Azm)

Maastricht, , Netherlands

Site Status

Isala Klinieken

Zwolle, , Netherlands

Site Status

Waikato Hospital

Hamilton, , New Zealand

Site Status

Palmerston North Hospital

Palmerston North, , New Zealand

Site Status

Centro Oncologico America

Panama City, , Panama

Site Status

The Panama Clinic

Panama City, , Panama

Site Status

Instituto Nacional de Enfermedades Neoplasicas

Lima, , Peru

Site Status

Clinica Anglo Americana - Centro de Investigacion Oncologia CAA

Lima, , Peru

Site Status

Clinica El Golf

San Isidro, , Peru

Site Status

Clinica Peruana Americana

Trujillo, , Peru

Site Status

University Of Santo Tomas

Manila, , Philippines

Site Status

Rizal Medical Center

Pasig, , Philippines

Site Status

Veterans Memorial Medical Ctr

Quezon City, Luzon, , Philippines

Site Status

Bialostockie Ctr Onkologii

Bialystok, , Poland

Site Status

Centrum Onkologii

Bydgoszcz, , Poland

Site Status

Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii

Gda?sk, , Poland

Site Status

Opolskie Centrum Onkologii

Opole, , Poland

Site Status

Narodowy Inst.Onkologii im.Sklodowskiej-Curie Panstw.Inst.Bad

Warsaw, , Poland

Site Status

NZOZ Mazowiecki Szpital Onkologiczny Uczelni Warszawskiej im. M. Sk?odowskiej-Curie

Wieliszew, , Poland

Site Status

Emergency University Bucharest Hospital

Bucharest, , Romania

Site Status

Oncology Inst. Cluj-Napoca

Cluj-Napoca, , Romania

Site Status

Prof. Dr. I. Chiricuta Institute of Oncology

Cluj-Napoca, , Romania

Site Status

Euroclinic Center of Oncology SRL

Iași, , Romania

Site Status

S.I. Russian Oncological Research Center n.a. N.N. Blokhin

Moscow, Moscow Oblast, Russia

Site Status

State Budget Institution of Healthcare of Stavropol region Pyatigorsk Oncology Dispensary

Pyatigorsk, Stavropol Kray, Russia

Site Status

Clinical Oncology Dispensary of Ministry of Health of Tatarstan

Kazan', Tatarstan Republic, Russia

Site Status

SBI of Healthcare Samara Regional Clinical Oncology Dispensary

Samara, , Russia

Site Status

SBI of Healthcare of Stavropol region Stavropol Regional Clinical Oncology Dispensary

Stavropol, , Russia

Site Status

Tula Regional Oncology Dispensary

Tula, , Russia

Site Status

Institute of Oncology Ljubljana

Ljubljana, , Slovenia

Site Status

National Hospital

Bloemfontein, , South Africa

Site Status

Wits Donald Gordon Clinical Trial Centre

Johannesburg, , South Africa

Site Status

Steve Biko Academic Hospital

Pretoria, , South Africa

Site Status

Seoul National University Bundang Hospital

Gyeonggi-do, , South Korea

Site Status

Seoul National Uni Hospital

Seoul, , South Korea

Site Status

Yonsei University Severance Hospital

Seoul, , South Korea

Site Status

Kyunghee University Hospital

Seoul, , South Korea

Site Status

Samsung Medical Centre

Seoul, , South Korea

Site Status

Korea University Anam Hospital

Seoul, , South Korea

Site Status

Hospital General Universitario de Elche

Elche, Alicante, Spain

Site Status

Hospital Universitario Son Espases

Palma de Mallorca, Balearic Islands, Spain

Site Status

Hospital Son Llatzer

Palma de Mallorca, Balearic Islands, Spain

Site Status

Corporacio Sanitaria Parc Tauli

Sabadell, Barcelona, Barcelona, Spain

Site Status

Hospital Universitario Marques de Valdecilla

Santander, Cantabria, Spain

Site Status

Hospital Provincial de Castellon

Castellon, Castellon, Spain

Site Status

Hospital Universitario Reina Sofia

Córdoba, Cordoba, Spain

Site Status

IInstituto Oncologico de San Sebastian, Oncologikoa

Donostia / San Sebastian, Guipuzcoa, Spain

Site Status

Hospital de Donostia

Donostia / San Sebastian, Guipuzcoa, Spain

Site Status

Complejo Hospitalario Universitario A Coruña (CHUAC, Materno Infantil), Oncología

A Coruña, LA Coruna, Spain

Site Status

Complejo Hospitalario Universitario de Santiago (CHUS)

Santiago de Compostela, LA Coruna, Spain

Site Status

Hospital Universitari Arnau de Vilanova de Lleida

Lleida, Lerida, Spain

Site Status

Hospital Clinico Universitario Virgen de la Victoria

Málaga, Malaga, Spain

Site Status

Hospital Universitario de Canarias

San Cristóbal de La Laguna, Tenerife, Spain

Site Status

Centro Oncológico Gallego José Antonio Quiroga y Piñeiro, Servicio de Oncologia

A Coruña, , Spain

Site Status

Hospital del Mar

Barcelona, , Spain

Site Status

Vall d'Hebron Institute of Oncology (VHIO), Barcelona

Barcelona, , Spain

Site Status

Hospital Clínic i Provincial

Barcelona, , Spain

Site Status

Hospital de la Santa Creu i Sant Pau

Barcelona, , Spain

Site Status

Hospital Duran i Reynals

Barcelona, , Spain

Site Status

Hospital Universitari Germans Trias i Pujol

Barcelona, , Spain

Site Status

Hospital Juan Ramon Jimenez

Huelva, , Spain

Site Status

Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico

Jaén, , Spain

Site Status

Centro Oncologico MD Anderson Internacional

Madrid, , Spain

Site Status

Hospital Ramon y Cajal

Madrid, , Spain

Site Status

Hospital Universitario Clínico San Carlos

Madrid, , Spain

Site Status

Hospital General Universitario Gregorio Marañon

Madrid, , Spain

Site Status

Hospital Universitario 12 de Octubre

Madrid, , Spain

Site Status

Centro Integral Oncologico Clara Campal (CIOCC)

Madrid, , Spain

Site Status

Hospital General Universitario J.M Morales Meseguer

Murcia, , Spain

Site Status

Hospital Clinico Universitario de Salamanca

Salamanca, , Spain

Site Status

Hospital Universitario Virgen Macarena

Seville, , Spain

Site Status

Hospital Universitario Virgen del Rocio

Seville, , Spain

Site Status

Hospital Univ. Nuestra Señora de Valme

Seville, , Spain

Site Status

Complejo Hospitalario de Toledo- H. Virgen de la Salud

Toledo, , Spain

Site Status

Instituto Valenciano Oncologia

Valencia, , Spain

Site Status

Hospital Clinico Universitario de Valencia

Valencia, , Spain

Site Status

Hospital Arnau de Vilanova (Valencia) Servicio de Oncologia

Valencia, , Spain

Site Status

Hospital Universitario la Fe

Valencia, , Spain

Site Status

Hospital Universitario Miguel Servet

Zaragoza, , Spain

Site Status

Sahlgrenska Universitetssjukhuset

Gothenburg, , Sweden

Site Status

Uni Hospital Linkoeping

Linköping, , Sweden

Site Status

Karolinska University Hospital

Stockholm, , Sweden

Site Status

Norrlands Universitetssjukhus, Umeå, Cancercentrum

Umeå, , Sweden

Site Status

Akademiska sjukhuset, Onkologkliniken

Uppsala, , Sweden

Site Status

Universitaetsspital Basel

Basel, , Switzerland

Site Status

Hôpitaux Universit. de Genève Gynécologique - Oncologie

Geneva, , Switzerland

Site Status

Luzerner Kantonsspital

Lucerne, , Switzerland

Site Status

Kantonsspital St. Gallen

Sankt Gallen, , Switzerland

Site Status

Brust-Zentrum Zürich AG Seefeldstrasse 214 Zürich

Zurich, , Switzerland

Site Status

Changhua Christian Hospital

Changhua, , Taiwan

Site Status

Kaohsiung Medical Uni Chung-Ho Hospital

Kaohsiung City, , Taiwan

Site Status

Taichung Veterans General Hospital

Taichung, , Taiwan

Site Status

National Cheng Kung Uni Hospital

Tainan, , Taiwan

Site Status

Veterans General Hospital

Taipei, , Taiwan

Site Status

National Taiwan Uni Hospital

Taipei, , Taiwan

Site Status

Tri-Service General Hospital, Division of General Surgery

Taipei, , Taiwan

Site Status

Chiang Rai Prachanukraw Hospital

Chiang Rai, , Thailand

Site Status

Lopburi Cancer Hospital

Lopburi, , Thailand

Site Status

Buddhachinaraj Phitsanulok Hospital

Phitsanulok, , Thailand

Site Status

Songklanagarind Hospital

Songkhla, , Thailand

Site Status

Surat Thani Hospital

Surat Thani, , Thailand

Site Status

Cherkassy Regional Oncological Hospital

Cherkassy, , Ukraine

Site Status

State Medical Academy

Dnipropetrovsk, , Ukraine

Site Status

Ivano-Frankivsk Regional Oncology Center

Ivano-Frankivsk, , Ukraine

Site Status

Kyiv City Clinical Oncological Center, Day Hospital Department for Oncological patients

Kiev, , Ukraine

Site Status

Volyn Regional Oncology Dispensary

Lutsk, , Ukraine

Site Status

Lvov State Regional Oncology Medical & Diagnostic Center

Lviv, , Ukraine

Site Status

Ternopil State Medical Academy

Ternopil, , Ukraine

Site Status

Royal Berkshire Hospital

Berkshire, , United Kingdom

Site Status

Velindre Cancer Centre

Cardiff, , United Kingdom

Site Status

Cheltenham General Hospital

Cheltenham, , United Kingdom

Site Status

Colchester General Hospital

Colchester, Essex, , United Kingdom

Site Status

University Hospital coventry

Coventry, , United Kingdom

Site Status

Western General Hospital

Edinburgh, , United Kingdom

Site Status

Royal Devon & Exeter Hospital

Exeter, , United Kingdom

Site Status

Ipswich Hospital

Ipswich, , United Kingdom

Site Status

St James Uni Hospital

Leeds, , United Kingdom

Site Status

St. Bartholomew'S Hospital

London, , United Kingdom

Site Status

UCL Hospital NHS Trust

London, , United Kingdom

Site Status

Royal Marsden Hospital

London, , United Kingdom

Site Status

Christie Hospital

Manchester, , United Kingdom

Site Status

The Clatterbridge Cancer Ctr For Oncolgy

Metropolitan Borough of Wirral, , United Kingdom

Site Status

Mount Vernon Hospital

Northwood, , United Kingdom

Site Status

Nottingham City Hospital

Nottingham, , United Kingdom

Site Status

Churchill Hospital

Oxford, , United Kingdom

Site Status

Peterborough City Hospital, Edith Cavell Campus

Peterborough, , United Kingdom

Site Status

Queen Alexandra Hospital

Portsmouth, , United Kingdom

Site Status

Royal Preston Hosp

Preston, , United Kingdom

Site Status

Weston Park Hospital

Sheffield, , United Kingdom

Site Status

Uni Hospital of North Staffordshire

Stoke-on-Trent, , United Kingdom

Site Status

Royal Marsden Hosp NHS Fnd

Sutton, , United Kingdom

Site Status

Royal Cornwall Hospital

Truro, , United Kingdom

Site Status

New Cross Hospital

Wolverhampton, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Australia Austria Belgium Bulgaria Canada Chile China Colombia Croatia Czechia Denmark El Salvador France Germany Guatemala Hong Kong Hungary Ireland Israel Italy Japan Mexico Netherlands New Zealand Panama Peru Philippines Poland Romania Russia Slovenia South Africa South Korea Spain Sweden Switzerland Taiwan Thailand Ukraine United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Loibl S, Jassem J, Sonnenblick A, Parlier D, Winer E, Bergh J, Gelber RD, Restuccia E, Im YH, Huang CS, Dalenc F, Calvo I, Procter M, Caballero C, Clark E, Raimbault A, McConnell R, Monturus E, de Azambuja E, Gomez HL, Bliss J, Viale G, Bines J, Piccart M; APHINITY Steering Committee and Investigators. Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update. J Clin Oncol. 2024 Nov;42(31):3643-3651. doi: 10.1200/JCO.23.02505. Epub 2024 Sep 11.

Reference Type DERIVED
PMID: 39259927 (View on PubMed)

de Azambuja E, Agostinetto E, Procter M, Eiger D, Ponde N, Guillaume S, Parlier D, Lambertini M, Desmet A, Caballero C, Aguila C, Jerusalem G, Walshe JM, Frank E, Bines J, Loibl S, Piccart-Gebhart M, Ewer MS, Dent S, Plummer C, Suter T; APHINITY Steering Committee and Investigators. Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial. ESMO Open. 2023 Feb;8(1):100772. doi: 10.1016/j.esmoop.2022.100772. Epub 2023 Jan 19.

Reference Type DERIVED
PMID: 36681013 (View on PubMed)

Gelber RD, Wang XV, Cole BF, Cameron D, Cardoso F, Tjan-Heijnen V, Krop I, Loi S, Salgado R, Kiermaier A, Frank E, Fumagalli D, Caballero C, de Azambuja E, Procter M, Clark E, Restuccia E, Heeson S, Bines J, Loibl S, Piccart-Gebhart M; APHINITY Steering Committee and Investigators. Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial. Eur J Cancer. 2022 May;166:219-228. doi: 10.1016/j.ejca.2022.01.031. Epub 2022 Mar 18.

Reference Type DERIVED
PMID: 35313167 (View on PubMed)

Bines J, Clark E, Barton C, Restuccia E, Procter M, Sonnenblick A, Fumagalli D, Parlier D, Arahmani A, Baselga J, Viale G, Reaby LL, Frank E, Gelber RD, Piccart M, Jackisch C, Petersen JA. Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer. Br J Cancer. 2021 Jul;125(1):38-47. doi: 10.1038/s41416-021-01323-y. Epub 2021 Apr 7.

Reference Type DERIVED
PMID: 33828257 (View on PubMed)

Piccart M, Procter M, Fumagalli D, de Azambuja E, Clark E, Ewer MS, Restuccia E, Jerusalem G, Dent S, Reaby L, Bonnefoi H, Krop I, Liu TW, Pienkowski T, Toi M, Wilcken N, Andersson M, Im YH, Tseng LM, Lueck HJ, Colleoni M, Monturus E, Sicoe M, Guillaume S, Bines J, Gelber RD, Viale G, Thomssen C; APHINITY Steering Committee and Investigators. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up. J Clin Oncol. 2021 May 1;39(13):1448-1457. doi: 10.1200/JCO.20.01204. Epub 2021 Feb 4.

Reference Type DERIVED
PMID: 33539215 (View on PubMed)

Bines J, Procter M, Restuccia E, Viale G, Zardavas D, Suter T, Arahmani A, Van Dooren V, Baselga J, Clark E, Eng-Wong J, Gelber RD, Piccart M, Mobus V, de Azambuja E; APHINITY Steering Committee and Investigators. Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. Clin Breast Cancer. 2020 Apr;20(2):174-181.e3. doi: 10.1016/j.clbc.2019.06.016. Epub 2019 Sep 5.

Reference Type DERIVED
PMID: 31924513 (View on PubMed)

Luo Y, Li W, Jiang Z, Zhang Q, Wang L, Mao Y, Tjan-Heijnen VCG, Im SA, McConnell R, Bejarano S, Fumagalli D, Bines J, Wang B, Garg A, Kirschbrown WP, Xu B. Pharmacokinetics of pertuzumab administered concurrently with trastuzumab in Chinese patients with HER2-positive early breast cancer. Anticancer Drugs. 2019 Sep;30(8):866-872. doi: 10.1097/CAD.0000000000000808.

Reference Type DERIVED
PMID: 31305270 (View on PubMed)

Kirschbrown WP, Kagedal M, Wang B, Lindbom L, Knott A, Mack R, Monemi S, Nijem I, Girish S, Freeman C, Fumagalli D, McConnell R, Jerusalem G, Twelves C, Baselga J, von Minckwitz G, Bines J, Garg A. Pharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study. Cancer Chemother Pharmacol. 2019 Jun;83(6):1147-1158. doi: 10.1007/s00280-019-03826-1. Epub 2019 Apr 11.

Reference Type DERIVED
PMID: 30976844 (View on PubMed)

von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med. 2017 Jul 13;377(2):122-131. doi: 10.1056/NEJMoa1703643. Epub 2017 Jun 5.

Reference Type DERIVED
PMID: 28581356 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TOC4939G

Identifier Type: OTHER

Identifier Source: secondary_id

2010-022902-41

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

BIG 4-11

Identifier Type: OTHER

Identifier Source: secondary_id

BO25126

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.